Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SX 682

Next Previous
Drug Profile

SX 682

Alternative Names: SX-682

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntrix Biosystems
  • Developer Boehringer Ingelheim; Bristol-Myers Squibb; National Cancer Institute (USA); Syntrix Biosystems; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Benzene derivatives; Boronic acids; Ethers; Fluorinated hydrocarbons; Fluorobenzenes; Pyrimidines; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Malignant melanoma; Myelodysplastic syndromes; Solid tumours
  • No development reported Pancreatic cancer

Most Recent Events

  • 29 Jan 2024 Syntrix Biosystems plans a phase II SYNERGY-201 trial for Prostate cancer (Metastatic-disease, Hormone refractory, Combination therapy) in the USA (PO) (NCT06228053)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Metastatic disease) in USA (PO, Pill)
  • 31 Aug 2023 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top